Cleerly raises $43 million to tackle heart attacks

New York-based Cleerly is now live following a $43 million Series B funding round led by Vensana Capital with participation from LRVHealth, New Leaf Venture Partners, DigiTx Partners, the American College of Cardiology, Cigna Ventures, and existing investors, bringing its total funding to $54 million.

Founded in 2017, Cleerly creates digital care for heart disease via its precision diagnostic solutions that enable phenotyping of coronary artery disease. Beyond end-to-end AI for deep coronary phenotyping, Cleerly’s solutions include tools for clinicians – such as primary care physicians or general cardiologists – to understand the importance of the data without having to understand advanced imaging. It also includes interactive and personalized, patient-facing tools to help improve health literacy and empower patients with knowledge. Finally, quantitative tools enable patients and their care team to track coronary artery disease changes over time.

“Advanced imaging has been key to diagnosing and preventing the most common causes of cancer for years, but we’re not using it yet to prevent the most common cause of death. We use 3D mammograms, colonoscopies and lung CT scans to find and prevent breast, colon and lung cancer, but we haven’t had similar capabilities for the world’s number one killer – heart disease. Through the application of artificial intelligence that is constantly being refined with our unprecedented volume of accruing and exclusive clinical data, Cleerly is finally bringing heart disease diagnosis and prevention into the twenty-first century.” – James K. Min, MD FACC, and founder and CEO of Cleerly.

“We see Cleerly as the future of how coronary artery disease will be evaluated, and we support the company’s mission to tailor a personalized approach to diagnosis, management and treatment, and to validate all of this with world-class clinical evidence of utility and cost-effectiveness. With Cleerly’s industry-leading technology platform and inherent value propositions, we believe Cleerly is ideally positioned to inform a new standard of care for how we manage coronary artery disease at scale.” – Justin Klein, MD, JD, Managing Partner at Vensana Capital.

“We are proud to be the partner of choice for companies like Cleerly who share our commitment in breaking boundaries and accelerating innovation to unlock bold, new opportunities that create better health for the people we serve. With these digital health partnerships and through our end-to-end care approach, we see significant opportunity to accelerate innovation in cardiovascular disease while improving patient experience, reducing costs and improving outcomes.” – Tom Richards, global lead, strategy and business development at Cigna.